ITM Obtains Exclusive Worldwide License from Debiopharm for CA IX-Targeted Peptide-based Radiopharmaceutical Programs Targeting Solid Tumors

ITM Isotope Technologies Munich SE (ITM) , a leading radiopharmaceutical biotech company and Debiopharm , a Swiss-based, global biopharmaceutical company, aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, toda…


– 출처 : https://www.newswire.co.kr/newsRead.php?no=996899&sourceType=rss

함께 보면 좋은 콘텐츠